Alicaforsen therapy in inflammatory bowel disease

Expert Opinion on Biological Therapy

Volumn 5, Issue 10, 2005, Pages 1387-1391

  Barish, Charles F ^a  

^a WAKE RESEARCH ASSOCIATES   (United States)

Author keywords

Alicaforsen; Biologic drugs; Crohn's disease; Intercellular adhesion molecule; Ulcerative colitis

Indexed keywords

ALICAFORSEN; ANTISENSE OLIGONUCLEOTIDE; C REACTIVE PROTEIN; ENEMA; INTERCELLULAR ADHESION MOLECULE 1; MESALAZINE; PLACEBO;

AREA UNDER THE CURVE; BLEEDING; CELL MIGRATION; CLINICAL TRIAL; CROHN DISEASE; CYTOKINE PRODUCTION; DRUG SAFETY; DRUG TOLERABILITY; ENTERITIS; FLUSHING; HUMAN; HYPERSENSITIVITY REACTION; INFECTION; LEUKOCYTE ADHERENCE; PARTIAL THROMBOPLASTIN TIME; PATHOGENESIS; PILOT STUDY; PROTEIN EXPRESSION; RASH; REVIEW; SIDE EFFECT; SINUSITIS; T LYMPHOCYTE; ULCERATIVE COLITIS;

CELL ADHESION MOLECULES; GASTROINTESTINAL AGENTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; THIONUCLEOTIDES;

EID: 27144444993     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.5.10.1387     Document Type: Review

References (11)

1. VAN ASSCHE G, VAN RANST M, SCIOT R et al.: Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohns disease. N. Engl. J. Med. (2005) 353:362-368.
2. YACYSHYN B, CHEY W, GOFF J et al.: Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease. Gut (2002) 51:30-36.
3. CHEY W, VOLFOVA M, KONECNY M et al.: Two Phase III studies of alicaforsen (ISIS-2302), an antisense oligonucleotide to human ICAM-1, in the treatment of moderate to severe Crohn's disease. Gastroenterology (2005) 128:A112.
4. VAN DEVENTER S, VOLFOVA M, FLISIAK R et al.: Phase II dose ranging, double-blind, placebo-controlled study of alicaforsen enema in subjects with acute exacerbation of mild to moderate left-sided ulcerative colitis. Gastroenterology (2005) 128:A74.
5. MINER P, NICHOLS T, SCHWARTZ H et aL: A Phase II trial to assess the safety and efficacy of two dose formulations of alicaforsen enema compared with mesalamine enema for acute left-sided ulcerative colitis. Gostroenterology (2005) 128:A74.
6. VAN ASSCHE G, RUTGEERTS P: Physiological basis for novel drug therapies used to treat the inflammatory bowel diseases. Am. J. Physiol. Gastrointest. Liver Physiol. (2005) 288:G169-G174.
7. MINER P, WEDEL M, BANE B, BRADLEY J: An enema formulation of alicaforsen, an antisense inhibitor of intercellular adhesion molecule-1, in the treatment of chronic, unremitting pouchitis. Aliment. Pharmocol. Ther. (2004) 19:281-286.
8. CROOKE S: Antisense strategies. Curr. Mol. Med. (2004) 4:465-487.
9. VAN DEVENTER S, TAMI J, WEDEL MK: A randomized, controlled, double blind, escalating dose study of alicaforsen enema in active ulcerative colitis. Gut (2004) 53:1646-1651.
10. RUTGEERTS P, VAN DEVENTER S, SCHREIBER S: Review article: the expanding role of biologic agents in the treatment of inflammatory bowel disease - focus on selective adhesion molecule inhibition. Aliment. Pharmacol. Ther. (2003) 17:1435-1450.
11. YACYSHYN B, BOWEN-YACYSHYN M, JEWELL L et al.: A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease. Gastroenterology (1998) 114:1133-1142.